Business Wire

CA-XPANSIV-CBL-HOLDING

27.7.2020 15:02:13 CEST | Business Wire | Press release

Share
XCHG Signs First XSignals Customers, Providing Actionable ESG Insights and Market Benchmarks

XCHG , the global marketplace for Intelligent Commodities™, today announced the launch of XSignals , a component of the company’s multi-sided platform that offers unprecedented clarity in the pricing and analysis of digital, ESG-inclusive commodities (d-ESGc ). These price signals—reported directly from open market activity—become benchmarks that enable vital ESG factors to be calculated into global trade.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005224/en/

XSignals' initial customers include leading firms engaged in providing trading services to sellers and buyers of digital environmental commodities like Renewable Energy Certificates and Carbon Offsets, with a pipeline of customers from industries making long-term environmental commitments, such as the aviation industry’s CORSIA accord.

“The markets we serve are incredibly dynamic, and our customers need to know where value is being created, as reflected in real-time prices,” said Andy Bose, Head of Ecosystems and Data Partnerships for XCHG. “With the launch of our XSignals platform, we provide an unparalleled understanding of the forces moving commodities markets, giving our customers comprehensive information to inform better decisions."

Inclusive of a broad range of asset classes and offerings, XSignals provides timely, transparent information to support trading, compliance, and risk-management decisions. XSignals translates ESG spot market price data into high-quality reference products, enabling global markets to accurately price ESG factors.

“Our aim in launching XSignals is to enhance the market's understanding of price and value for the broad range of environmental products transacted on our exchange,” Bose said. “We’re offering unique insight into where prices are coming from, empowering a deeper understanding of where value will be in the future.”

XCHG’s first product offerings include market data—trade orders and consummated transactions—in US RECs and international carbon from the company’s spot exchange, CBL Markets . XSignals provides daily data on price, volume, time, market depth, and other key indicators that offer real-time insight into value, as reflected in the marketplace. XSignals also offers access to a historical data set that covers the last 30 months of transactions.

“In order for the global economy to transition to a sustainable trajectory, indicative price signals for ESG factors in food, energy, and materials are needed to direct capital flows over time,” said XCHG CEO Joe Madden. “XSignals provides the foundation for this transition through the consistent, reliable representation of objective value for ESG factors in commodity pricing.”

XCHG plans to deepen the XSignals offering with more capabilities, including tools for data analysis and visualization, allowing customers to both self-serve and take advantage of XCHG’s understanding of how that data will be of maximum value.

“XSignals is another step toward delivering on our mission of more accurately valuing the commodities at the base of the global economy in the century ahead,” said Madden.

About XCHG

Xpansiv CBL Holding Group (XCHG) is the world’s first commodity marketplace built for a data-rich, resource-constrained world. We bring transparency to global markets through innovative, ESG-inclusive commodity products and price information. XCHG.net

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye